BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8308858)

  • 1. A new potent and selective histamine H3 receptor agonist, 4-(1H-imidazol-4-ylmethyl)piperidine.
    Vollinga RC; de Koning JP; Jansen FP; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1994 Feb; 37(3):332-3. PubMed ID: 8308858
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
    Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
    J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.
    Kitbunnadaj R; Hashimoto T; Poli E; Zuiderveld OP; Menozzi A; Hidaka R; de Esch IJ; Bakker RA; Menge WM; Yamatodani A; Coruzzi G; Timmerman H; Leurs R
    J Med Chem; 2005 Mar; 48(6):2100-7. PubMed ID: 15771452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
    Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
    Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
    J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.
    Ishikawa M; Furuuchi T; Yamauchi M; Yokoyama F; Kakui N; Sato Y
    Bioorg Med Chem; 2010 Jul; 18(14):5441-8. PubMed ID: 20541426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
    De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of clozapine with the histamine H3 receptor in rat brain.
    Rodrigues AA; Jansen FP; Leurs R; Timmerman H; Prell GD
    Br J Pharmacol; 1995 Apr; 114(8):1523-4. PubMed ID: 7541279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
    Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
    J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel histamine H3 receptor antagonists: synthesis and evaluation of formamidine and S-methylisothiourea derivatives.
    Goto T; Sakashita H; Murakami K; Sugiura M; Kondo T; Fukaya C
    Chem Pharm Bull (Tokyo); 1997 Feb; 45(2):305-11. PubMed ID: 9118445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
    Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
    J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE.
    De Esch IJ; Mills JE; Perkins TD; Romeo G; Hoffmann M; Wieland K; Leurs R; Menge WM; Nederkoorn PH; Dean PM; Timmerman H
    J Med Chem; 2001 May; 44(11):1666-74. PubMed ID: 11356102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
    Geyer R; Kaske M; Baumeister P; Buschauer A
    Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
    Wijtmans M; Celanire S; Snip E; Gillard MR; Gelens E; Collart PP; Venhuis BJ; Christophe B; Hulscher S; van der Goot H; Lebon F; Timmerman H; Bakker RA; Lallemand BI; Leurs R; Talaga PE; de Esch IJ
    J Med Chem; 2008 May; 51(10):2944-53. PubMed ID: 18433114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Camelin JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2009 Apr; 17(8):3037-42. PubMed ID: 19329325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.